You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Ultra-Lightweight, High-Efficiency Epitaxial Lift-Off Solar Cells and Arrays

    SBC: MICROLINK DEVICES INC            Topic: N14AT003

    MicroLink Devices and the University of Notre Dame propose to develop an ultra-lightweight, high-efficiency, GaAs-based, multi-junction solar cell that will be suitable for use in future platforms requiring very high specific power (>3.0 kW/kg) and very high areal power density (>370 W/m2). We will achieve this result by reducing the metal content of MicroLinks current inverted metamorphic (IMM), ...

    STTR Phase I 2014 Department of DefenseNavy
  2. Development of a Safer Lithium-ion (Li-ion) Battery for Naval Aircraft Applications Through Thermal Management Design

    SBC: TEXAS RESEARCH INSTITUTE , AUSTIN, INC.            Topic: N14AT006

    Texas Research Institute Austin, Inc. (TRI/Austin) is developing a lithium-ion battery module that will manage individual cell thermal runaways in two ways. The active management path will be to monitor the internal temperature of the cell and remove the cell from the charging/discharging circuit if anode or cathode temperatures exceed specified temperatures. Removal from the charging/discharging ...

    STTR Phase I 2014 Department of DefenseNavy
  3. Combining GaN and SiGe MMICs for Efficient and Innovative Radar Systems

    SBC: RDRTEC INCORPORATED            Topic: N14AT007

    This effort proposes to design, develop and fabricate prototype SiGe MMICs that when combined with GaN MMICs forms the basis for additional simultaneous modes and more efficiency for the C-band Radar Automatic Collision Avoidance System (RACAS). The addition of these MMICs will enable digitally controlled pulse mode interleaving and switchable and simultaneous polarizations for enhanced Coherent A ...

    STTR Phase I 2014 Department of DefenseNavy
  4. More Efficient GaN- SiGe based MMICs for Communication and Radar Systems

    SBC: EPISENSORS INC            Topic: N14AT007

    Active Electronic Scanned Array (AESA) radars play a strategic role in surveillance and reconnaissance. A GaN based T/R circuit will be radiation-hard but difficult to integrate with the remainder of the signal chain due to incompatible technologies. SiGe HBT technology, with its high frequency performance and the ability to blend in with CMOS, can act as a bridge between the high frequency III-V ...

    STTR Phase I 2014 Department of DefenseNavy
  5. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Ex vivo purging strategy for treatment of multiple myeloma

    SBC: DNATRIX INC            Topic: NCI

    DESCRIPTION (provided by applicant): The ultimate goal of this application is to develop a novel ex vivo purging method using myxoma virus (MYXV), a rabbit-specific poxvirus, to improve the clinical outcomes in treatment of multiple myeloma (MM). MM is aclonal plasma cell malignancy that has to date resisted essentially all therapeutic strategies. Currently, the standard of care for patients wit ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Removal of Amyloid-beta Peptides from the Alzheimer's Brain

    SBC: WE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): As the Alzheimer's disease (AD) population is growing rapidly, currently there are no cure treatments. The goal of this resubmitted STTR proposal is to conduct a preclinical study with pramlintide to prove a potential treatment for AD. We have revised the proposal significantly according to the reviewers' comments. Pramlintide is an FDA approved drug ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis

    SBC: Exicure, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government